

1 **SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with**
2 **antigenically similar SARS-CoV-2 variants**

3
4 John Kubale¹, Charles Gleason², Juan Manuel Carreño², Komal Srivastava², PARIS Study
5 Team², Aubree Gordon^{1*}, Florian Krammer^{2,5*}, Viviana Simon^{2,3,4,5*}

6
7 **Affiliations**

8 ¹Department of Epidemiology, School of Public Health, University of Michigan, Michigan

9 ²Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

10 ³Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Icahn
11 School of Medicine at Mount Sinai, New York, NY, USA

12 ⁴Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai,
13 New York, NY, USA

14 ⁵Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at
15 Mount Sinai, New York, NY, USA

16
17 PARIS Study Team: Hala Alshammary, Angela A. Amoako, Dalles Andre, Mahmoud H.
18 Awawda, Katherine F. Beach, Dominika A Bielak, Maria C. Bermúdez-González, Gianna Y. Cai,
19 Rachel L Chernet, Christian Cognigni, Emily D. Ferreri, Daniel L. Floda, Joshua Hamburger,
20 Hisaaki Kawabata, Giulio Kleiner, Neko Lyttle, Wannu A Mendez, Lubbertus CF Mulder, Ismail
21 Nabeel, Annika Oostenink, Ariel Raskin, Aria Rooker, Kayla Russo, Ashley Beathrese T.
22 Salimbangon, Miti Saksena, Gagandeep Singh, Levy A. Sominsky, Daniel Stadlbauer, Johnston
23 Tcheou, Ania Wajnberg

24
25 **Shared first authors (contributed equally): John Kubale, Charles Gleason**

26 **Shared corresponding authors (contributed equally*):** Aubree Gordon, Florian Krammer,
27 Viviana Simon

28
29 **Keywords:** SARS-CoV-2, COVID-19, spike-binding antibodies, protection, modeling

30 **Running title:** Durability of SARS-CoV-2 antibodies

31 **40-word summary:** The levels of SARS-CoV-2 spike binding antibodies mounted upon
32 infection with ancestral SARS-CoV-2 variants are highly variable, stabilize at an individual level
33 after three months and provide protection from infection with homologous virus.

34 **ABSTRACT**

35 The PARIS (**P**rotection **A**ssociated with **R**apid **I**mmunity to **S**ARS-CoV-2) cohort follows health
36 care workers with and without documented coronavirus disease 2019 (COVID-19) since April
37 2020. We report our findings regarding SARS-CoV-2 spike binding antibody stability and
38 protection from infection in the pre-variant era. We analyzed data from 400 healthcare workers
39 (150 seropositive and 250 seronegative at enrollment) for a median of 84 days. The SARS-CoV-
40 2 spike binding antibody titers were highly variable with antibody levels decreasing over the first
41 three months, followed by a relative stabilization. We found that both more advanced age (>40
42 years) and female sex were associated with higher antibody levels (1.6-fold and 1.4-fold
43 increases, respectively). Only six percent of the initially seropositive participants “seroreverted”.
44 We documented a total of 11 new SARS-CoV-2 infections (ten naïve participants, one
45 previously infected participant without detectable antibodies, $p < 0.01$) indicating that spike
46 antibodies limit the risk of re-infection. These observations, however, only apply to SARS-CoV-2
47 variants antigenically similar to the ancestral SARS-CoV-2 ones. In conclusion, SARS-CoV-2
48 antibody titers mounted upon infection are stable over several months in most people and
49 provide protection from infection with antigenically similar viruses.

50

51 **INTRODUCTION**

52 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the
53 coronavirus disease 2019 (COVID-19) pandemic with over 430 million infections (WHO
54 dashboard, February 25th 2022) since it emerged in late 2019 (1, 2). In the vast majority of
55 individuals, infection with SARS-CoV-2 leads to the induction of a specific adaptive immune
56 response including spike binding as well as neutralizing antibodies (3, 4). Indeed, we found that
57 over 90% of individuals infected during the first wave in New York City (NYC) had robust
58 antibody titers as measured using an enzyme-linked immunosorbent assay (ELISA, >30,000
59 cross-sectional measurements) (4, 5). The durability and protective effect of such antibody
60 responses remains a topic of active investigation even as we move into the third year of the
61 pandemic. An initial study (6) reported fast waning of SARS-CoV-2 binding antibodies but others
62 report spike binding IgG antibodies being detectable months after infection (7-9).

63 The first SARS-CoV-2 infection in New York State was officially detected at the Mount
64 Sinai Health System in NYC on February 29th, 2020 although SARS-CoV-2 had likely been
65 introduced to the local communities weeks to months earlier (10, 11). Indeed, the New York
66 metropolitan area emerged as one of the early COVID-19 epicenters in the US. This initial
67 COVID-19 wave was exponential in growth and nearly overwhelmed our local health care
68 systems due to the high number of patients with severe COVID-19 manifestations resulting in
69 infection fatality rates ranging between 1 and 1.5% (11, 12). It was at that point in time (April
70 2020) that we started enrollment for the PARIS (**P**rotection **A**ssociated with **R**apid **I**mmunity to
71 **S**ARS-CoV-2) cohort to follow health care workers (HCWs) of the Mount Sinai Health System
72 with and without documented COVID-19 over time. Full-length spike binding IgG antibody titers
73 were measured every two to four weeks using a sensitive and specific quantitative ELISA (13).
74 In addition, data on potential exposures as well as clinical signs and symptoms suggestive of
75 SARS-CoV-2 infection were collected at the same time intervals.

76 Here we report our findings regarding the kinetics of SARS-CoV-2 spike binding IgG
77 antibody titers over time and the protection from reinfection in a high-risk work environment.

78 **MATERIAL AND METHODS**

79 **Description of the PARIS cohort:** The PARIS study enrolled healthcare workers with and
80 without prior SARS-CoV-2 infection to study the durability and effectiveness of the immune
81 response to SARS-CoV-2. A total of 501 participants were enrolled between April 2020 and
82 August 2021. The study protocol was reviewed and approved by the Mount Sinai Hospital
83 Institutional Review Board (IRB-20-03374). All participants provided written informed consent.
84 Samples were coded prior to processing and testing. Blood was collected at 2-4 week intervals
85 regardless of the serostatus at enrollment. For this analysis, the cohort was restricted to 400
86 participants enrolled prior to SARS-CoV-2 vaccination with, at least, four weeks of follow-up or
87 two study visits prior to vaccination. At the time of enrollment, 150/400 participants were
88 seropositive for SARS-CoV-2 spike binding antibodies while 250/400 were seronegative. Most
89 participants had no known immunosuppressive conditions/co-morbidities. We used the data
90 from 2,106 distinct study visits from these 400 participants to evaluate risk of SARS-CoV-2
91 infection and seroreversion. From this dataset, we selected a subset of 137 participants with
92 known dates of COVID-19 (symptom onset, positive SARS-CoV-2 nucleic acid amplification test
93 (NAAT), or positive SARS-CoV-2 antibody test results) and, at least, two pre-vaccine study
94 visits with SARS-CoV-2 antibody measurements. The data of 813 distinct study visits from these
95 137 seropositive participants provide the basis for the modeling SARS-CoV-2 spike-binding IgG
96 antibody durability.

97
98 **Identification of new SARS-CoV-2 infections in PARIS.** One of the 11 participants who were
99 infected during the observation period was diagnosed as part of the study using viral diagnostic
100 NAAT while nine participants tested positive for SARS-CoV-2 outside of the Mount Sinai Health
101 System. One asymptomatic infection was identified by seroconversion (from negative to a titer
102 of 1:400).

103

104 **SARS-CoV-2 full-length spike binding antibody measurements.** Antibody titers were
105 determined using a two-step ELISA protocol (13) in which sera are screened at a single dilution
106 (1:50) for IgG against the recombinant receptor binding domain (RBD) of the spike protein from
107 SARS-CoV-2, followed by detection of antibodies against the full-length spike protein. End-point
108 titers were determined by serially diluting sera (from 1:80 to 1:102,400). Briefly, 96-well
109 microtitre plates (Thermo Fisher) were coated with 50 μ l/well of recombinant RBD (2 μ g/ml)
110 overnight at 4 °C. Plates were washed three times with phosphate-buffered saline (PBS; Gibco)
111 supplemented with 0.1% Tween-20 (PBS-T; Fisher Scientific) using an automatic plate washer
112 (BioTek). Plates were then blocked with PBS-T containing 3% milk powder (American Bio) for 1
113 hour. Sera was heat-inactivated and serially diluted (3-fold) in PBS-T 1%-milk powder, starting
114 at 1:50 initial dilution for RBD ELISA and at 1:80 dilution for full-length spike ELISA. Samples
115 were added to the plates and incubated for 2-hours. Plates were washed three times with PBS-
116 T and 50 μ l/well of anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in
117 goat; Sigma, A0293) diluted to 1:3,000 in PBS-T, 1% milk powder, were added to each well.
118 After 1-hour incubation at room temperature, plates were washed three times with PBS-T and
119 100 μ l/well of SigmaFast o-phenylenediamine dihydrochloride (Sigma) were added for 10min,
120 followed by addition of 50 μ l/well of 3M hydrochloric acid (Thermo Fisher) to stop the reaction.
121 Optical density was measured at a wavelength of 490 nm using a plate reader (BioTek).
122 Endpoint titers, expressed as the last dilution before the signal dropped below an OD490nm of
123 0.15, were calculated in excel and data was plotted using GraphPad Prism 9.

124
125 **Assessment and modeling of SARS-CoV-2 Spike binding antibody durability over time.**

126 To assess how spike antibody titers changed over time we fit an additive mixed model using the
127 mgcv package (version 1.8-36) for R (version 4.1.1). Participants were excluded from the model
128 if they never developed a detectable titer (at least 1:80) during follow-up or if the data regarding
129 when they were infected (illness onset, NAAT positive, or antibody positive date) was missing.

130 Day 0 was defined as the reported symptom onset date or the date of positive SARS-CoV-2
131 diagnostic test.

132 Spike titers (ranging from 1:80 to 1:6,400) were transformed to the log₂ scale so that a 1-unit
133 increase corresponded to a doubling of antibody titer. Sex (female, male), age (<40 years, 40+
134 years), and baseline titer (<1:800, ≥1:800) were included as covariates in the model, along with
135 a random intercept for participant ID to account for repeated measures. Finally, a penalized
136 spline term was included to model antibody titer over time. We fit this model in two ways: 1)
137 assuming that antibody decay occurred at the same rate over time regardless of baseline titer,
138 2) allowing antibody decay over time to vary by baseline titer. In the second model a distinct
139 smoothing function was fit for each baseline titer group. Data is available upon request, and the
140 code used for modeling is available on GitHub at <https://github.com/jkubale/paris>.

141
142 **Determination of the frequency of spike binding antibody seroreversion.** Seropositive
143 participants who initially had measurable spike binding antibodies but subsequently had spike
144 binding antibody levels below the limit of detection (1:80) on two consecutive visits were defined
145 as having seroreverted. We examined the probability of seroreversion over time for those with
146 low (<1:800) and high (≥1:800) baseline titers by calculating the probability of survival (not
147 seroreverting) via the Kaplan-Meier estimator.

148
149 **Assessment of protection against re-infection.** We explored whether participants with a
150 detectable antibody titer had a lower probability of incident SARS-CoV-2 infection. New SARS-
151 CoV-2 infections were identified by positive NAAT or by SARS-CoV-2 antibody seroconversion.
152 The participant immune status was based on the most recent spike binding antibody titer
153 preceding the infection. Participants with detectable spike binding antibody titers were
154 compared to those without detectable titers using Fisher's Exact Test. All analyses were
155 performed using R version 4.1.1.

156 **RESULTS**

157 We analyzed the spike binding IgG antibody levels of 400 PARIS participants with (N:
158 150) or without previous COVID-19 (N: 250) collected every two to four weeks for a median of
159 84 days (IQR: 55-169) from April 2020 to August 2021. The majority of participants were female
160 (68%) with a median age of 35 years (range: 19-75; interquartile range [IQR]: 30-45). The
161 demographics of the cohort are summarized in **Table 1**. Approximately a third of the participants
162 self-reported as performing high-risk tasks as part of their work assignments. Most participants
163 with spike binding antibodies at study enrollment (92.7%, 139/150) were infected during the first
164 pandemic wave when NYC was one of the epicenters of the pandemic (March-May 2020). Of
165 the remaining 11 participants, seven were infected in the summer and fall of 2020 prior to
166 enrolling into PARIS and four participants did not recall having any symptoms suggestive of
167 COVID-19. Two PARIS cohort datasets were used to analyze durability and effectiveness of
168 serological responses (Protection Dataset, Antibody Durability Dataset, **Figure 1A, Table 1**).

169 To model spike-binding antibody kinetics, we analyzed a total of 813 distinct spike
170 binding measurements from 137 participants (median: five study visits; IQR: 4-8 visits per
171 participant, longitudinal follow-up of two to six months up to 400 days post-infection, see **Table**
172 **1, Supplemental Figure 1**). The date of symptom onset or positive NAAT was used as Day 0
173 when available. Alternatively, we used the date of first positive SARS-CoV-2 antibody assay as
174 Day 0 for 21 participants. Spike binding IgG antibody titers were highly variable among COVID-
175 19 survivors, with titers ranging between 1:80 and 1:6,400. The majority (59.1%) of participants
176 had SARS-CoV-2 binding antibody titers above 1:800 at their baseline visit. We noted that the
177 antibody levels decreased over the first three months, followed by a relative stabilization that
178 persisted up to one year post-infection (**Figure 1B**). Given the large variation in the initial
179 antibody levels, we modeled whether the slopes for those with titers above 1:800 were different
180 from the slopes measured for those with lower antibodies (less than 1:800). SARS-CoV-2 spike

181 binding antibody kinetics between the two groups were comparable, with the initial decay being
182 more pronounced in the high antibody group (**Figure 1C**).

183 We next tested whether demographic variables such as sex or age were associated with
184 the durability of spike antibody durability by modeling the impact of sex and age on antibody
185 levels over the course of the observation period. We found that more advanced age (e.g., 40
186 years or older) was associated with 1.62-fold higher antibody levels (95% CI: 1.20-2.19)
187 compared to younger participants. Sex was also associated with the level of SARS-CoV-2 spike
188 antibodies, with antibody levels being 1.40-fold higher in female participants (95% CI: 1.03-1.92)
189 than male participants (**Supplementary Table S1**).

190 All the participants with documented SARS-CoV-2 infection also mounted detectable
191 antibody responses but we wondered whether seropositive individuals would turn seronegative
192 during the observation period. We found that 6% (8/137) of the initially seropositive participants
193 in the Antibody Durability Dataset tested negative on subsequent visits occurring over up to
194 eleven months of study follow-up. All eight of these participants were initially in the lower
195 baseline antibody group (below 1:800 titer) pointing to a significantly higher risk of seroreversion
196 for individuals with initially lower antibody titers (**Figure 2**, Kaplan-Meier estimate).

197 Finally, we tested whether spike-binding IgG antibodies were associated with protection
198 from re-infection with genetically similar SARS-CoV-2 variants. Between July 2020 and August
199 2021, we documented a total of 11 new SARS-CoV-2 infections in PARIS participants (**Figure**
200 **3A**). Of note, 10/11 of these infections occurred at a time when only ancestral viral variants
201 circulated in the NY metropolitan area (**Figure 3A**). All but one of the SARS-CoV-2 infections
202 occurred in naïve participants. One infection was found in a participant with prior COVID-19,
203 albeit without detectable antibodies at time of re-infection (**Figure 3B**). Thus, detectable spike-
204 binding IgG antibodies mounted upon infection are associated with significant protection from
205 re-infection (Fisher's Exact Test, $p=0.001$) in this pre-vaccine and pre-Omicron era of the
206 COVID-19 pandemic.

207 **DISCUSSION**

208 Several studies have evaluated the durability of serum SARS-CoV-2 IgG antibodies (14).
209 While immune responses to SARS-CoV-2 infection and vaccination and their respective
210 protective effects have been analyzed at rapid speed and in much detail, many open questions
211 remain. We leveraged the fact that most seropositive PARIS participants were infected in the
212 first pandemic wave (March-April 2020) with very homogenous SARS-CoV-2 strains (15). An
213 additional strength of the PARIS cohort is the frequent, longitudinal sample and data collection
214 (every 2-4 weeks), which allows for a high level of granularity in the modeling of the durability
215 and effectiveness of SARS-CoV-2 antibody responses. We first evaluated the stability of spike-
216 binding IgG antibody titers over time. Typical antibody responses to infection are characterized
217 by an initial strong peak, driven by short-lived plasmablasts in the peripheral blood circulation,
218 followed by a decline and an eventual stabilization at a level of antibody that is produced by
219 long-lived plasmablasts in the bone marrow (16-18). This was exactly the pattern that we
220 observed in our analysis: high SARS-CoV-2 antibody titers declined initially but stabilized over
221 the following months. Overall, seroreversion was rare with only 6% of the COVID-19 survivors
222 having antibody levels wane to below the level of detection of our sensitive full-length spike IG
223 binding antibody ELISA. Interestingly, there were large differences in the spike-binding antibody
224 titers across participants with those 40 years and older having higher antibody titers compared
225 to younger individuals. This phenomenon has been observed before (19, 20). Our observation
226 that female participants have higher antibody titers than male participants stands in contrast to
227 several previous studies reporting that males have higher SARS-CoV-2 antibody levels (4). The
228 PARIS cohort comprises mostly younger and overall healthy health care workers with almost
229 exclusively mild infections, so it is conceivable that this sex difference becomes less apparent
230 when more severe COVID-19 manifestations known to result in higher antibody levels (20) are
231 included in the analysis. Of note other than the magnitude, there was no sizable difference in
232 the kinetics of antibody levels depending on age or sex. Additional studies in longitudinal

233 cohorts with as frequent sampling as done in the PARIS cohort are needed to independently
234 replicate our observations.

235 Several studies from the pre- (20-26) and post-Delta (B.1.617.2) (27, 28) era suggest
236 that protection from reinfection ranges around 80-90% if the circulating SARS-CoV-2 variants
237 are antigenically similar to the ones responsible for the initial infections. Only the appearance of
238 Omicron has led to an increase of reinfections (28, 29). Our cohort study supports this notion
239 since we did not document any reinfections in study participants who were previously infected
240 and maintained detectable levels of spike binding antibodies. Indeed, ten naïve individuals and
241 one individual with an initially low titer who sero-reverted prior to re-infection were infected
242 during the observation period. These findings suggest significant protection from reinfection and
243 hint at the importance of the level of spike-binding antibody titers in protection. Of note, the
244 presence of spike-binding antibodies was also correlated with protection in several other studies
245 (21, 30-32). Antibody titers against the receptor binding domain and the full-length spike, as well
246 as neutralizing antibodies, have recently been proposed as correlates of protection of vaccine
247 induced immunity (33-35). Importantly, the data in these studies were generated before the
248 Omicron variants started to circulate at larger scale in our community. Similarly, the current
249 analysis was conducted prior to the circulation of SARS-CoV-2 variants of concern in the NYC
250 metropolitan area. Our data underscores that spike binding antibodies protect against infection
251 with antigenically similar viral strains. Protection against heterologous, antigenically distinct
252 variants such as Omicron is likely limited based on the pronounced reduction in virus
253 neutralization (36-39).

254 This study has several strengths. First, the prospective nature of the cohort allowed us to
255 assess how antibody responses against SARS-CoV-2 following natural infection changed over
256 time. Second, the repeated sampling/testing of this study provides a perspective on a much
257 more granular scale than previous analyses. Finally, this study is based on data collected prior
258 to the introduction of SARS-CoV-2 vaccines and the wide circulation of variants of concern that

259 are highly antigenically distinct (e.g., Omicron). As such, it provides a useful baseline against
260 which newer data can be compared to answer important questions regarding the relative
261 severity of new variants, the strength and durability of antibody responses against SARS-CoV-2
262 variants, and the impact of immune histories on the breadth of immune responses.

263 This analysis did, however, also have a few limitations. First, since we started enrollment
264 during the first wave, a good portion of participants were unable to get molecular tests at the
265 time of infection and we relied on retrospective reports of clinical signs and symptoms
266 suggestive of COVID-19 for illness onset date. As such, recall bias in reported illness onset is a
267 possibility. However, we anticipate that this exerted only a minor impact on our conclusions
268 given the relatively homogenous exposures of participants who are all health care workers.
269 Second, with healthcare worker vaccination beginning in December 2020 we were unable to
270 effectively assess how circulating variants of concern may affect one's risk of re-infection
271 following natural infection. The increase in vaccinated participants (excluded from this analysis),
272 while fortunate, also resulted in a smaller sample size at the end of the follow-up period
273 extending into August 2021.

274 In conclusion, our study shows that SARS-CoV-2 infection provides strong protection
275 from reinfection and this protection may be associated with the presence of spike binding
276 antibodies. In addition, it suggests that antibody levels induced by infection with ancestral
277 SARS-CoV-2 variants are relatively stable over time and that the rate of seroreversion is low
278 when measuring SARS-CoV-2 spike binding IgG antibodies.

279 **ACKNOWLEDGEMENTS**

280 We thank the study participants for their generosity and willingness to participate in longitudinal
281 COVID-19 research studies. None of this work would be possible without their contributions.

282 We very appreciative of the support of the Mount Sinai's leadership throughout the COVID-19
283 pandemic. We want to especially thank Drs. Peter Palese, Carlos Cordon-Cardo, Dennis
284 Charney, David Reich and Kenneth Davis. We would also like to thank Daniel Caughey for
285 expert administrative assistance and Dr. Andrew Brouwer for his thoughtful comments and
286 suggestions. This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative
287 Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work
288 was also partially funded by the NIAID Centers of Excellence for Influenza Research and
289 Response (CEIRR) contract 75N93021C00014 as well as by anonymous donors. This work is
290 part of the NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) program.

291 **CONFLICT OF INTEREST STATEMENT**

292 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-
293 CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457,
294 63/020,503 and 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional
295 Application Number: 63/251,020) which list Florian Krammer as co-inventor. Viviana Simon is
296 also listed on the serological assay patent application as co-inventor. Patent applications were
297 submitted by the Icahn School of Medicine at Mount Sinai. Mount Sinai has spun out a
298 company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted
299 for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Third Rock Ventures,
300 Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models
301 of SARS-CoV-2. Aubree Gordon serves on a scientific advisory board for Janssen and has
302 consulted for Gilead Sciences.

303 **REFERENCES**

- 304 1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected
305 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 306 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
307 associated with a new coronavirus of probable bat origin. *Nature*. 2020.
- 308 3. Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, et al. Serologic
309 responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.
310 *EBioMedicine*. 2020;59:102915.
- 311 4. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt A, et al.
312 Humoral response and PCR positivity in patients with COVID-19 in the New York City region,
313 USA: an observational study. *Lancet Microbe*. 2020;1(7):e283-e9.
- 314 5. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, et al. Robust
315 neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*.
316 2020;370(6521):1227-30.
- 317 6. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological
318 assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020.
- 319 7. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to
320 SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529).
- 321 8. Grandjean L, Saso A, Ortiz AT, Lam T, Hatcher J, Thistlethwayte R, et al. Long-Term
322 Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following
323 Infection with SARS-CoV-2. *Clin Infect Dis*. 2021.
- 324 9. Carreño JM, Mendu DR, Simon V, Shariff MA, Singh G, Menon V, et al. Longitudinal
325 analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple
326 serology platforms. *iScience*. 2021;24(9):102937.
- 327 10. Hernandez MM, Gonzalez-Reiche AS, Alshammary H, Fabre S, Khan Z, van De Guchte
328 A, et al. Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave. *Nat*
329 *Commun*. 2021;12(1):3463.
- 330 11. Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, et al. Repeated
331 cross-sectional sero-monitoring of SARS-CoV-2 in New York City. *Nature*. 2021;590(7844):146-
332 50.
- 333 12. Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. Estimating the
334 infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a
335 model-based analysis. *Lancet Infect Dis*. 2021;21(2):203-12.

- 336 13. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al.
337 A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*.
338 2020;26(7):1033-6.
- 339 14. Egbert ER, Xiao S, Colantuoni E, Caturegli P, Gadala A, Milstone AM, et al. Durability of
340 Spike Immunoglobulin G Antibodies to SARS-CoV-2 Among Health Care Workers With Prior
341 Infection. *JAMA Netw Open*. 2021;4(8):e2123256.
- 342 15. Gonzalez-Reiche AS, Hernandez MM, Sullivan MJ, Ciferri B, Alshammary H, Obla A, et
343 al. Introductions and early spread of SARS-CoV-2 in the New York City area. *Science*.
344 2020;369(6501):297-301.
- 345 16. Laidlaw BJ, Ellebedy AH. The germinal centre B cell response to SARS-CoV-2. *Nat Rev*
346 *Immunol*. 2022;22(1):7-18.
- 347 17. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2
348 infection induces long-lived bone marrow plasma cells in humans. *Nature*. 2021.
- 349 18. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of
350 high-affinity human monoclonal antibodies against influenza virus. *Nature*. 2008;453(7195):667-
351 71.
- 352 19. Bag Soytas R, Cengiz M, Islamoglu MS, Uysal BB, Ikitimur H, Yavuzer H, et al. Does the
353 COVID-19 seroconversion in older adults resemble the young? *J Med Virol*. 2021;93(10):5777-
354 82.
- 355 20. Maier HE, Kuan G, Saborio S, Carrillo FAB, Plazaola M, Barilla C, et al. Clinical
356 Spectrum of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Protection From
357 Symptomatic Reinfection. *Clinical Infectious Diseases*. 2021.
- 358 21. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2
359 infection rates of antibody-positive compared with antibody-negative health-care workers in
360 England: a large, multicentre, prospective cohort study (SIREN). *Lancet*.
361 2021;397(10283):1459-69.
- 362 22. Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler-Schwetz V, Trummer C, et al. SARS-
363 CoV-2 re-infection risk in Austria. *Eur J Clin Invest*. 2021;51(4):e13520.
- 364 23. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al.
365 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*.
366 2020.
- 367 24. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who
368 Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clin*
369 *Infect Dis*. 2021;73(10):1882-6.

- 370 25. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of
371 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in
372 Denmark in 2020: a population-level observational study. *Lancet*. 2021.
- 373 26. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Association
374 of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection. *JAMA Intern Med*.
375 2021;181(5):672-9.
- 376 27. Pouwels KB, Pritchard E, Matthews PC, Stoesser N, Eyre DW, Vihta KD, et al. Effect of
377 Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in
378 the UK. *Nat Med*. 2021;27(12):2127-35.
- 379 28. Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et
380 al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant
381 in South Africa. *medRxiv*. 2021:2021.11.11.21266068.
- 382 29. Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al.
383 Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. *N Engl J Med*.
384 2022.
- 385 30. Krammer F. Correlates of protection from SARS-CoV-2 infection. *Lancet*.
386 2021;397(10283):1421-3.
- 387 31. Letizia AG, Ge Y, Vangeti S, Goforth C, Weir DL, Kuzmina NA, et al. SARS-CoV-2
388 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
389 *Lancet Respir Med*. 2021.
- 390 32. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, et al.
391 Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery
392 vessel outbreak with high attack rate. *J Clin Microbiol*. 2020.
- 393 33. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
394 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
395 infection. *Nat Med*. 2021.
- 396 34. Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadzka D, et al. Towards
397 a population-based threshold of protection for COVID-19 vaccines. *Vaccine*. 2022;40(2):306-15.
- 398 35. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising
399 antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of
400 boosting: a meta-analysis. *Lancet Microbe*. 2022;3(1):e52-e61.
- 401 36. Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly
402 neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature*. 2021.

403 37. Juan Manuel Carreño, Hala Alshammary, Johnstone Tcheou, Gagandeep Singh, Ariel
404 Raskin, Hisaaki Kawabata, et al. Activity of convalescent and vaccine serum against SARS-
405 CoV-2 Omicron. Nature. 2021;doi: <https://doi.org/10.1038/d41586-021-03846-z>.

406 38. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2
407 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell.
408 2022;185(3):467-84.e15.

409 39. Muik A, Lui BG, Wallisch AK, Bacher M, Mühl J, Reinholz J, et al. Neutralization of
410 SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science.
411 2022;375(6581):678-80.

412

413 **Tables**

414 **Table 1: Characteristics of the PARIS participants included in the Protection Dataset (A;**
 415 **N=400) as well as in the Antibody Durability Dataset (B; N=137).**

416

A: Protection Dataset			
	Total	Seronegative	Seropositive
Number of Participants	400 (100.0%)	250 (62.5%)	150 (37.5%)
Sex			
Female	273 (68.3%)	175 (70.0%)	98 (65.3%)
Male	126 (31.5%)	74 (29.6%)	52 (34.7%)
Prefer Not to Say	1 (0.3%)	1 (0.4%)	0 (0.0%)
Age			
<40	250 (62.5%)	162 (64.8%)	88 (58.7%)
40+	149 (37.3%)	87 (34.8%)	62 (41.3%)
Missing	1 (0.3%)	1 (0.4%)	0 (0.0%)
Days Enrolled (median, IQR)	84 (55-169.25)	84 (55.25-174)	84 (55-167)
Seroreversion	9 (2.3%)	-	9 (6.0%)
B: Antibody Durability Dataset			
	Total	High baseline titer (800+)	Low baseline titer (<800)
Number of Participants	137 (100.0%)	81 (59.1%)	56 (40.9%)
Sex			
Female	89 (65.0%)	59 (72.8%)	30 (53.6%)
Male	48 (35.0%)	22 (27.2%)	26 (46.4%)
Age			
<40	80 (58.4%)	37 (45.7%)	43 (76.8%)
40+	57 (41.6%)	44 (54.3%)	13 (23.2%)
Days Enrolled (median, IQR)	84 (56-168)	108 (56-192)	69 (55-112)
Days between SO^b and Enrollment	154 (91-203)	147 (63-196)	182 (133-217)
Baseline SARS-CoV-2 Antibody Titer^c	1:730 (2.67)	1:1419 (1.93)	1:279(1.52)
Seroreversion	8 (5.8%)	0 (0.0%)	8 (14.3%)

^a N (%)

^b SO = symptom onset: median (IQR)

^c Geometric mean (Standard Deviation)

417

418 **Figure legends**

419

420 **Figure 1: Modeling SARS-CoV-2 antibody durability in PARIS participants**

421 A: Overview of the PARIS cohort datasets (protection, antibody durability) selected for the
422 analysis of humoral responses mounted upon infection.

423 B: Durability of SARS-CoV-2 spike binding antibodies over time. SARS-CoV-2 IgG binding
424 antibody dynamics after infection were described in 137 PARIS participants by an additive
425 mixed model. The early waning period is followed by stabilization. The date of SARS-CoV-2
426 infection was determined by a positive nucleic acid amplification test, onset of COVID-19
427 symptoms, or the date of first positive antibody test. Most participants were infected in the first
428 wave of the pandemic.

429 The limit of detection of the SARS-CoV-2 IgG antibody ELISA is set at a titer of 1:80. The blue
430 line represents the mean antibody titer value predicted by the model and the light blue shaded
431 region represents the 95% confidence interval of the mean.

432 C: SARS-CoV-2 antibody durability depends on the initial levels of antibodies.

433 The antibody durability group was split by the antibody titer at enrollment (pink: $\geq 1:800$, N: 81;
434 orange: $< 1:800$, N: 56). Both groups demonstrate broadly similar dynamics, with the early
435 waning period being most evident in the group with higher initial SARS-CoV-2 spike binding
436 antibody titers. Titers equal to/or above 1:800 were defined as high.

437 The pink and orange lines represent the mean antibody titer value predicted by the model and
438 the light pink/orange shaded regions represent the 95% confidence interval of the mean.

439

440

441 **Figure 2: Risk of seroreversion in the antibody durability dataset**

442 The Kaplan-Meier estimate indicates that the risk of seroreversion was significantly higher for
443 the participants with lower antibody titer at the time study enrollment (N=56 <1:800 titer
444 [orange], N=81 >1:800 titer [pink]). Of the 137 participants included in the antibody durability
445 dataset, only eight [6%] participants seroreverted, all of which were initially in the lower antibody
446 titer group.

447

448

449 **Figure 3: SARS-CoV-2 infections occurring in PARIS participants.**

450 A: Summary of the new infections documented in the protection dataset (N=400). The
451 circulating viral variants, the month of infection, the sex of the infected participants and the
452 COVID-19 severity is listed for the 11 SARS-CoV-2 infections documented in the protection
453 dataset between April 2020 and August 2021.

454 B: Graphic representation of the frequency of SARS-CoV-2 infections in the seropositive
455 (N=149, orange diamonds) and seronegative (N=251, blue diamond) study participants.
456 Participants who seroreverted are indicated by the orange/blue symbol. On-study infections
457 occurred in 11 study participants without detectable SARS-CoV-2 spike binding antibodies
458 (turquoise circles). 10/11 were naïve (blue diamond symbols) and only one participant had a
459 documented prior COVID-19 but no antibodies at the time of infection.

460

461

462

463

464

465

466

467 **Supplemental Data**

468

469 **Supplemental Table S1: Additive mixed model results regarding variables influencing the**
470 **level of SARS-CoV-2 spike binding IgG antibodies.**

471 The model indicates significant effects on SARS-CoV-2 antibody levels due to both age (>40
472 years of age) and sex (female). Significance was set at $p < 0.05$. Estimates are on a log 2 scale.

473

	<i>Estimate</i>	<i>Std. Error</i>	<i>t value</i>	<i>p value</i>
(Intercept)	8.5592	0.2171	39.434	< 2e-16 ***
Sex (Female)	0.4868	0.2299	2.118	0.03453 *
Age (>40 yrs)	0.6983	0.2210	3.159	0.00165 **

474

475

476

477 **Supplemental Figure legends**

478


479 **Supplemental Figure S1: Duration of study follow-up prior for unvaccinated PARIS**
480 **participants included in the protection dataset**

481 (A) The time between first and final pre-vaccine antibody measurements for each participant is
482 shown graphically. The total length of follow-up for unvaccinated participants varies substantially
483 since the SARS-CoV-2 vaccine rollout for health care workers started in the middle of
484 December 2020.


485 (B) Enrollment in the PARIS cohort and follow up are shown. PARIS began in April 2020 and
486 continued recruitment throughout the year. The graph summarizes all the pre-vaccination visits
487 for each participant. The number of unvaccinated participants in PARIS declined sharply when
488 SARS-CoV-2 vaccinations became available in December 2020 limiting the number of follow up
489 visits included in the study. Vaccination became mandatory for Mount Sinai staff members in
490 September 2021.

Kubale et al., Figure 1


A




B



C



Kubale et al., Figure 2




Kubale et al.

Figure 3

A

Month	Ancestral SARS-CoV-2 variants			Delta VOC
	Nov-20	Dec-20	Jan-21	Aug-21
# Primary Infections	3	4	2	1
# Re-infections	0	1	0	0
Female	1	4	1	1
COVID-19 severity	mild	mild	mild	mild

B



- ◆ Naïve (n=250)
- ◆ Ab+ at Baseline, Seropositive Throughout (n=141)
- ◆ Ab+ at Baseline, Sero-reversion (n=9)
- ◆ Infection on Study (n=11)

Kubale et al.

Supplemental Figure 1

